Polygenic score prediction captures nearly all common genetic risk for Alzheimer's disease by Escott-Price, V et al.
lable at ScienceDirect
Neurobiology of Aging 49 (2017) 214.e7e214.e11Contents lists avaiNeurobiology of Aging
journal homepage: www.elsevier .com/locate/neuagingBrief communicationPolygenic score prediction captures nearly all common genetic risk
for Alzheimer’s disease
Valentina Escott-Price a,*, Maryam Shoai b, Richard Pither c, Julie Williams a,
John Hardy b,**
a Institute of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics & Genomics, Cardiff University, Cardiff, UK
b Institute of Neurology, University College London, London, UK
cCytox Ltd, UK, Oxford, UKa r t i c l e i n f o
Article history:
Received 3 May 2016
Received in revised form 14 July 2016
Accepted 15 July 2016




Heritability* Corresponding author at: Institute of Psycholo
Neurosciences, MRC Centre for Neuropsychiatric Ge
University, Cardiff CF24 4HQ, UK. Tel.: þ44292068842
** Corresponding author at: Institute of Neurology, U
Tel.: þ442034484722; fax: þ442078331016.
E-mail addresses: EscottPriceV@cardiff.ac.uk (V. Es
(J. Hardy).
0197-4580/ 2016 The Author(s). Published by Elsevie
http://dx.doi.org/10.1016/j.neurobiolaging.2016.07.018a b s t r a c t
We estimate the maximum prediction accuracy for the risk of Alzheimer’s disease based on disease
prevalence and heritability of liability. We demonstrate that the recently reported AUC values for pre-
dicting of Alzheimer’s disease using polygenic scores reach about 90% of the estimated maximum ac-
curacy that can be achieved by predictors of genetic risk based on genomic proﬁles.
 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
With increasing longevity due to better medical care, the preva-
lence of Alzheimer’s disease (AD) is increasing. Hope for ﬁnding
preventative and clinical therapies lies in the ability to gain a better
understanding of the underlying biology of the disease, and genetics
can provide a valuable starting point for advancement. Despite
enormous efforts across the research community, and the successful
identiﬁcation of dozens of risk loci identiﬁed genes that associate
with AD, the impact on therapies or prevention is negligible.
Rare monogenic forms of AD, the majority of which are
attributable to mutations in 1 of 3 genes, APP, PSEN1, and PSEN2,
exist, but common, late-onset AD is genetically complex. Along
with the APOE polymorphism (Corder et al., 1993), 20 common
susceptibility loci (ABCA7, BIN1, CD33, CLU, CR1, CD2AP, EPHA1,
MS4A4, PICALM, HLA-DRB5/DRB1, SORL1, PTK2B, SLC24A4/RIN3,
ZCWPW1, SELF1, NME8, FERMT2, CASS4, INPP5D,MEF2C, CD33) have
been identiﬁed to be associated with AD (Harold et al., 2009;
Hollingworth et al., 2011; Lambert et al., 2009, 2013; Naj et al.,gical Medicine and Clinical
netics & Genomics, Cardiff
9; fax: þ442920687068.
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IGHV1-67 were reported as gene-based genome-wide signiﬁcant,
as well as ZNF3 gene and a cluster of genes on chromosome 11
(SPI1-MTCH2), shown as gene-based genome-wide signiﬁcant
associationwith ADwhich are in proximity with those detected by
genome-wide signiﬁcant single nucleotide polymorphisms (SNPs;
Escott-Price et al., 2014). Another moderately rare variant in
TREM2 has also shown evidence for association (Guerreiro et al.,
2013). However, rare risk-increasing variants may not be tagged
by single SNPs, as for example, the case for CLU in which signiﬁ-
cant enrichment of rare variants in cases was observed indepen-
dent of the single locus genome-wide association signal (Bettens
et al., 2012). Disease risk may reﬂect the coaction of several loci
but the number of loci involved at the individual or the population
levels are unknown, as is the spectrum of allele frequencies and
effect sizes (Risch, 1990).
Recently, it has been reported that there is a large polygenic
contribution to the overall heritable risk of AD (Escott-Price et al.,
2015), implying that the genetic architecture of AD includes many
common variants of small effect that is likely to reﬂect a large
number of susceptibility genes and a complex set of biological
pathways related to disease. The approach using the polygenic risk
score (PRS), introduced by the International Schizophrenia Con-
sortium (International Schizophrenia et al., 2009), has facilitated
the creation of genomic proﬁles which combine the effects of many
associated genetic variants to predict risk of disease.under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ROC curve analysis and area under the curve (AUC) provides the
most widely accepted test of prediction accuracy in correctly classi-
fying diseased and unaffected individuals. We were interested in
investigating the maximal possible predictive power (AUCmax) of
genomic proﬁles based on disease prevalence and heritability of AD.
AUCmax is deﬁned as the maximum AUC that could be achieved for a
diseasewhen the test classiﬁer is a perfect predictorof genetic risk. To
evaluate the maximal prediction accuracy of the genetic variability,
we used the approach introduced by (Wray et al., 2010). This
approach requires estimates of theheritability of liability (i.e., genetic
variances on the liability scale) using genome-wide SNPs and disease
prevalence. It has been reported that for AD the proportion of total
variation tagged by all SNPs is 0.24 (SE 0.03; Lee et al., 2013). This
variancewas estimated using a restrictedmaximum likelihood (Yang
et al., 2011) algorithm ﬁtting all SNPs simultaneously in a data set of
3290 cases and 3849 controls (Genetic and Environmental Risk for
Alzheimer’s disease [GERAD1] consortium [Harold et al., 2009]), us-
ing a lifetime ADprevalence of 2% to transform the heritability on the
observed scale to that on the liability scale (Brookmeyer et al., 1998).
The disease prevalence (K) is the other parameter, which has to
be speciﬁed for the estimation of AUCmax. The prevalence of AD in
the population depends verymuch on age. Recent estimates show a
3%, 17%, and 33% prevalence in the 65e74, 75e84, and 85þ age
groups, respectively (Hebert et al., 2013). For the AUCmax calcula-
tions, we used the online calculator (Wray et al., 2010) and per-
formed those for AD lifetime prevalence 2% and as well as
prevalences for 3 age groups above.
Then we compared the theoretical AUCmax with the empirical
AUC estimates provided in (Escott-Price et al., 2015). In that report,
the empirical AUCs were calculated in a subsample of GERAD1
participants, for whom APOE genotype data were available (3049
cases and 1554 controls, mean age was 73 years [SD ¼ 9.6]). Since
the genetic architecture of AD may be different for early, medium,
and late onset, therefore the heritability and, consequently, the
prediction accuracy may also vary with age. Thus to make the
comparison of theoretical and empirical estimates fair, we ﬁrst
matched the prevalence parameter used for heritability of liability
estimation and AUCmax, and second, we compared the obtained
maximum prediction accuracies with the empirical ones in the
corresponding age groups. The heritability of liability h2l for the
disease prevalences (3%, 17%, and 33%) was re-calculated according




Pð1PÞ , where P is
the proportion of cases in the whole GERAD1 data set (p¼ 30%), K is
disease prevalence, h2l is the estimate of heritability on the observed
scale, and z2 is the height of the standard normal probability den-
sity function at the truncation threshold K.
3. Results
The results are summarized in Table 1. Our analysis revealed
that the maximum prediction accuracy is AUCmax ¼ 82% (95%Table 1
The maximum area under the ROC curve (AUC) possible, based upon the AD prevalence
2% lifetime prevalence 3% pre
All SNPs APOE regiona APOE & GWAS locib
h2l 0.24 [0.18e0.30] 0.048 [0.032e0.063] 0.051 [0.039e0.063] 0.27 [0
AUCmax 0.82 [0.78e0.85] 0.65 [0.62e0.67] 0.66 [0.64e0.67] 0.82 [0
h2l [95%CI], estimated genetic variance proportional to the total variance on the liability sc
on the genomic proﬁle on heritability and disease prevalence with 95% conﬁdence inter
Key: AUC, area under the curve; SNPs, single nucleotide polymorphisms.
a The APOE region is deﬁned between 44,400KB-46,500KB on chromosome 19 for the
b GWAS loci are deﬁned as  500KB of both sides of the GWAS signiﬁcant SNPs (LamCI: 78%e85%) for a lifetime AD prevalence 2%. The best prediction
accuracy of the PRS reported for that data set (Escott-Price et al.,
2015) is AUC ¼ 74.5% (95% CI ¼ 0.73e0.76, see Fig. 1), calculated
based on prediction results of logistic regression when APOE e4, e2,
and PRS for SNPs with AD association p-values <0.5 were included
in the model (SNPs with r2 > 0.2 to the best associated SNP in the
region of 1 MB were pruned out). Note that the PRS there included
proxies to the 20 GWAS SNPs reported in (Lambert et al., 2013) and
were based on the full IGAP data set, which includes the GERAD
data set. To exclude the potential bias introduced by this fact, we
recalculated the prediction accuracy based on SNPs selected only
from the independent data set (IGAP-noGERAD), and the AUC was
quite similar 73.7 (95% CI: 0.72e0.75). The 74% AUC accounts for
about 90% (74% out of 82%) of the prediction accuracy, which can be
reached using genetic data as a predictor.
In Table 1, we also present genetic variance estimates for APOE
locus alone and for APOE and 20 genome-wide association study
(GWAS) signiﬁcant loci. Our estimates were similar to (Lee et al.,
2013; Ridge et al., 2013), which were obtained using the same
and an independent Alzheimer’s Disease Genetics Consortium data
sets, respectively. In addition, our results show the maximum AUC
for APOE and APOE þ GWAS loci, AUCmax ¼ 65% (95% CI: 0.62e0.67)
and 66% (95% CI: 0.64e0.67), respectively. A possible explanation is
that in the (Escott-Price et al., 2015) article, the authors used
directly genotyped e4 and e2 alleles, whereas the genetic variance
estimates here were obtained with their proxies.
In the age group 65e74 (disease prevalence K ¼ 3%), the AUCmax
came to 82% (see Table 1). This is very close to the actual AUC ¼
79.2% calculated in the younger group of subjects (Supplemental
Table 5 in [Escott-Price et al., 2015]). Correcting for the bias in
empirical AUC estimation due to not fully independent top
signiﬁcant SNPs, we get the AUC in this age group is 75% (95% CI:
73%e77%) which accounts for 91.5% of the AUCmax in this age group.
4. Conclusions
In summary, we have shown ﬁrst that the pattern of the
polygenic risk score prediction accuracy was similar to theoret-
ical estimates of the accuracy based on heritability and AD
prevalence. Second, the actual AUC values achieved for polygenic
risk score when only w87,600 SNPs (Escott-Price et al., 2015)
were included are quite close to the upper limit (AUCmax) that
could be achieved from that data set given the genetic epide-
miology of the disease, namely disease prevalence and herita-
bility. Thus, suggesting that while as yet unknown, the majority
of the remaining common variant susceptibility loci are
captured, either directly or indirectly within our polygenic risk
score model for this data set.
A possible limitation of our study is that the predictive modeling
(Escott-Price et al., 2015) and the estimates of the heritability of
liability (Lee et al., 2013) were performed mostly on the same
subjects (GERAD1 sample). However, we believe that this fact does
not affect our results since the SNPs selection and the individualand heritability estimates (Lee et al., 2013)
valence (age 65e74) 17% prevalence (age 75e84) 33% prevalence (age 85þ)
.20e0.33] 0.45 [0.34e0.57] 0.55 [0.41e0.68]
.78e0.86] 0.84 [0.80e0.88] 0.86 [0.81e0.90]
ale with 95% conﬁdence intervals; AUCmax [95%CI], the maximum value of AUC based
vals.
APOE locus.
bert et al., 2013). APOE region and GWAS loci were pruned with r2 ¼ 0.2.
Fig. 1. Polygenic Risk score based estimation of AUC and AUCmax for 2% lifetime
prevalence of AD. Abbreviations: AD, Alzheimer’s disease; AUC, area under the curve.
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modeling were based on an independent sample (IGAP without
GERAD1 [Escott-Price et al., 2015]).
Considerable effort is being made through exome and genome
sequencing to identify further risk loci and risk alleles for AD. Our
analysis suggests that there likely to be additional genome-wide
signiﬁcant loci for the disease; however, identiﬁcation of
genome-wide signiﬁcant loci, common or rare, will require sub-
stantial increase in sample sizes. This is consistent with the rela-
tively low number of new ﬁndings achieved through the extensive
AD sequencing efforts that have already been initiated
(Fuchsberger et al., 2016). There will, almost certainly, be other
allelic variants that inﬂuence disease risk identiﬁed at the known
loci, however, since linkage disequilibrium between low fre-
quency causal variants and commonly genotyped SNPs is low
(Wray, 2005), it is likely that those variants will be rare. Our
analysis also indicates that the contribution of any new ﬁndings,
not already captured by polygenic risk score, to the overall pre-
diction of AD risk is likely to be small and will be attributed to rare
variants.
One can also further enhance the AUC by adding more envi-
ronmental and/or clinical information. For example, the addition of
age and gender to the prediction model increased the AUC value
from 74.5% to 78.2% (95% CI: 77%e80%; Escott-Price et al., 2015). It is
possible now to add to the genomic proﬁle nonheritable genetic
variants, such as de novo copy number variants or DNAmethylation
status. These variables do not contribute to heritability and there-
fore such genomic proﬁles could exceed the AUCmax presented here.
The prediction accuracy could be hampered by the heterogeneity in
AD deﬁnition. For example, (Corneveaux et al., 2010) have shown
increased association effect sizes for neuropathologically conﬁrmed
AD cases and controls compared to international consortia which
generally use clinically diagnosed samples. We advocate that more
accurate classiﬁcation of disease will further increase the risk pre-
diction accuracy.
In conclusion, this analysis suggests that the polygenic risk
proﬁling captures the SNP-heritability very well and is quitesuitable for AD genetic risk prediction purpose. However, herita-
bility estimates are very uncertain, especially in a late-onset dis-
ease. We would advocate, in view of our analysis, that the
additional contribution of new AD loci or new pathways which are
undiscovered (Jones et al., 2010), is not crucial for genetic pre-
diction due to the small increase in AUC that this would achieve.
The additional variability at the loci, which are at least partially
captured by the polygenic risk SNPs, will account for small pro-
portions of SNP-heritability (Steinberg et al., 2015). Further anal-
ysis will clarify the signiﬁcance of loci that do not currently reach
genome-wide signiﬁcance in the biological pathways we have
established as being important in disease. This will further inform
the understanding of disease mechanisms and targets for future
treatments.
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